Accord Healthcare Recalls Aripiprazole Tablets Due to Manufacturing Deviations
Accord Healthcare is recalling approximately 1.1 million bottles of Aripiprazole 5mg tablets due to Good Manufacturing Practice deviations identified during an FDA inspection. No illnesses or injuries have been reported.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall triggered by CGMP deviations on a prescription psychiatric medication. Manufacturing process violations represent a risk of harm to medication quality and safety. No illnesses or injuries reported, limiting the score to 3 per the rubric criterion for risk-of-harm products without reported injury.
Plain-English summary
Accord Healthcare, Inc. is recalling Aripiprazole Tablets, USP 5 mg distributed in the United States, Puerto Rico, and Canada. The recall involves approximately 1,109,904 bottles across multiple affected batches.
The recall was initiated following an FDA inspection that identified deviations from Current Good Manufacturing Practice (CGMP) standards. These manufacturing process violations could potentially affect the quality and safety of the medication.
No illnesses or injuries related to this recall have been reported.
The recalled product
- Product
- ARIPIPRAZOLE (ARIPIPRAZOLE)
- Brand
- ARIPIPRAZOLE
- Manufacturer
- Accord Healthcare, Inc.
- Hazard
- cgmp-deviation
- product-quality
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Batches: a) P2004259
- P2004260
- P2004261
- Exp. Date 7/31/2023
- P2006799
- P2101391
- Exp. Date 11/30/2023
- P2100826
- Exp. Date 1/31/2024
- P2101320
- Exp. Date 2/28/2024
- P2102510
- P2102409
- P2102407
- Exp. Date 3/31/2024
- P2102410
- P2105251
- P2105252
- P2105253
- Exp. Date 7/31/2024
UPCs (2)
- 316729279109
- 316729279017
Distribution
Distribution scope not specified by the agency.
Related recalls
Same brand · ARIPIPRAZOLE
- HighAripiprazole tablets recalled nationwide due to excess active ingredient
FDA (Drugs) · 2025-09-24
- ModeratePrescription Aripiprazole tablets recalled nationwide for storage temperature deviation
FDA (Drugs) · 2024-01-03
- HighAntipsychotic Drug Recalled for Failed Quality Control Test
FDA (Drugs) · 2023-04-26
- ModeratePrescription drug aripiprazole tablets recalled for manufacturing practice deviations
FDA (Drugs) · 2023-03-08
- ModerateAripiprazole Tablets Recalled Following FDA Inspection for Manufacturing Deviations
FDA (Drugs) · 2023-03-08
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27